Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This study highlights that traumatic anserine folliculosis is a benign condition often seen in young males, which can be diagnosed without invasive biopsies using clinical examination and dermoscopy.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

This study suggests that clinically apparent fragile hair in children is rarely linked to trichothiodystrophy, and the tiger-tail pattern is not wholly specific to this diagnosis.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This report suggests a possible association between temporal triangular alopecia and sebaceous nevus, and identifies a pinkish background as a new trichoscopic finding for TTA.

This study found that key amino acids lost from hair due to weathering can be successfully reintroduced through cosmetic treatments, improving hair strength and aesthetics.

This meta-analysis found a significant positive association between frontal fibrosing alopecia and both sunscreen and moisturizer use, with the moisturizer association significant only in males.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This treatise provides guidelines and suggestions for the safe practice of follicular unit transplantation but reports no new clinical results.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This study found that the free androgen index (FAI) is a superior marker of hyperandrogenism in men with premature androgenetic alopecia compared to DHEAS and testosterone levels.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.

The study found that Temporal Triangular Alopecia often starts in early childhood, mainly affects the left side of the scalp, and has no effective treatment except surgery.

This study in Morocco found that all women with frontal fibrosing alopecia presented frontotemporal hairline recession, with trichoscopic features such as perifollicular erythema and follicular hyperkeratosis being indicative of the condition, and suggested a potential link between cosmetic products or emotional factors and the disease.

Tofacitinib may effectively treat folliculitis decalvans.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

This review discusses potential therapeutic options for frontal fibrosing alopecia by exploring distinct signaling pathways and cellular players, but reports no new clinical findings and emphasizes the need for further trials.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study found that TRF1 plays a crucial role in maintaining pluripotency and stem cell compartments, but it is not a suitable in vivo telomere length marker.

This study observed that frontal fibrosing alopecia is increasingly diagnosed in Italian Caucasian females, often showing premenopausal onset and eyebrow alopecia as an early sign.

This study found that oral isotretinoin significantly reduced symptoms in nearly 90% of patients with frontal fibrosing alopecia, affecting both facial papules and hair loss.

This article discusses the advancements in follicular unit transplantation for hair restoration and reports no clinical results; it emphasizes improved aesthetic outcomes using updated techniques.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.